CO4820397A1 - TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig - Google Patents

TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig

Info

Publication number
CO4820397A1
CO4820397A1 CO97024335A CO97024335A CO4820397A1 CO 4820397 A1 CO4820397 A1 CO 4820397A1 CO 97024335 A CO97024335 A CO 97024335A CO 97024335 A CO97024335 A CO 97024335A CO 4820397 A1 CO4820397 A1 CO 4820397A1
Authority
CO
Colombia
Prior art keywords
igg
preparation
patient
fighting
aim
Prior art date
Application number
CO97024335A
Other languages
English (en)
Inventor
Louis Martin Renzetti
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO4820397A1 publication Critical patent/CO4820397A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para combatir el asma en pacientes que sufran de unestado asmático, el cual método incluye la administración a dicho paciente de una composición que contiene una preparación compuesta por una o más proteínas en quiméricas de unión a TNF-a, cada una de las cuales proteínas en dicha preparación esta compuesta por la porción soluble de la proteína receptora de TNF p55 fusionada a una IgG, en la que dicha IgG fusionada contiene todos los dominios de IgG excepto el primer dominio de IgG de la región constante de la cadena pesada de la IgG, conteniendo dicha composición un vector farmacéutico terapéuticamente inerte, y siendo dicha preparación administrada a dicho paciente con el objetivo de suministrar a dicho paciente una cantidad efectiva de dicha preparación de proteína quimérica, con el objetivo de combatir dicho estado asmático.
CO97024335A 1996-05-08 1997-05-07 TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig CO4820397A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1684296P 1996-05-08 1996-05-08

Publications (1)

Publication Number Publication Date
CO4820397A1 true CO4820397A1 (es) 1999-07-28

Family

ID=21779275

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97024335A CO4820397A1 (es) 1996-05-08 1997-05-07 TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig

Country Status (15)

Country Link
EP (1) EP0910413A2 (es)
JP (1) JP2000510113A (es)
KR (1) KR20000010825A (es)
CN (1) CN1233189A (es)
AR (1) AR007020A1 (es)
AU (1) AU725408B2 (es)
BR (1) BR9708928A (es)
CA (1) CA2253557A1 (es)
CO (1) CO4820397A1 (es)
HR (1) HRP970224A2 (es)
MA (1) MA24169A1 (es)
PE (1) PE70698A1 (es)
TR (1) TR199802238T2 (es)
WO (1) WO1997041895A2 (es)
ZA (1) ZA973843B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2316545A1 (en) * 1997-12-29 1999-07-08 Regeneron Pharmaceuticals, Inc. Novel nucleic acid and polypeptide with homology to the tnf-receptors
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
ES2304602T3 (es) * 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2009004134A (es) 2006-10-20 2009-08-12 Biogen Idec Inc Tratamiento de trastornos de desmielinizacion con el receptor de linfotoxina beta soluble.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5684222A (en) * 1993-01-22 1997-11-04 Ontario Cancer Institute Mutant mouse having a disrupted TNFRp55
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
BR9508419A (pt) * 1994-07-22 1997-11-18 Hoffmann La Roche Composições farmacêuticas compreendendo uma proteina de ligação de tnf quinerica
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
BR9708928A (pt) 2000-05-09
MA24169A1 (fr) 1997-12-31
PE70698A1 (es) 1998-11-18
KR20000010825A (ko) 2000-02-25
EP0910413A2 (en) 1999-04-28
CN1233189A (zh) 1999-10-27
AR007020A1 (es) 1999-10-13
TR199802238T2 (xx) 1999-02-22
HRP970224A2 (en) 1998-04-30
AU2776497A (en) 1997-11-26
ZA973843B (en) 1997-11-10
AU725408B2 (en) 2000-10-12
WO1997041895A2 (en) 1997-11-13
JP2000510113A (ja) 2000-08-08
WO1997041895A3 (en) 1998-03-12
CA2253557A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
GB2301366B (en) Antibodies against E-selectin
HK1022440A1 (en) Combination therapy using a tnf binding protein for treating tnf-mediated diseases
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
BR9907189A (pt) Produtos da fração lipìdica do carotenóide de pepino do mar e métodos de uso
UA32636C2 (uk) Засіб для зниження вмісту холестерину в сироватці крові людини
AR024074A1 (es) FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS.
DK0865294T3 (da) Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
NO20003550D0 (no) Farmasøytiske sammensetninger og anvendelse herav
NO933171L (no) Anvendelse av molekyler rettet mot celleoverflatereseptorer for behandling av virussykdommer
ES2080307T3 (es) Composiciones farmaceuticas.
HUP9902429A2 (hu) TNF-receptor-asszociált faktor (TRAF) modulátorok előállítása és alkalmazása
CA2062582A1 (en) Methods and substances for recruiting therapeutic agents to solid tissues
EP0797999A3 (en) Formulations of obesity protein
EP1003552A4 (en) ANTIBODIES DIRECTED AGAINST LO-CD2a AND USE THEREOF TO INHIBIT THE ACTIVATION AND PROLIFERATION OF T-LYMPHOCYTES
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
HUP0002062A2 (hu) Eljárás metabolikus csontbetegségek diagnózisára
CO4820397A1 (es) TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig
AU9363398A (en) Hepatitis c receptor protein cd81
Lopez-Gonzalez et al. Presence of the pineal hormone melatonin in rat cochlea: its variations with lighting conditions
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
NO951762L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer, omfattende et aktivt koagulasjonsfremmende stoff